Figure 5.

Tepotinib overcomes MET-mediated sotorasib resistance in vivo

Antitumor activity and tolerability of sotorasib and tepotinib as mono- and combination therapy was investigated in mice bearing subcutaneous NCI-H358 tetON-MET xenografts. Ten mice were randomized to each treatment. Mice were fed with a doxycycline-containing diet and compounds were applied daily via oral gavage.

(A) Graph displaying the tumor volumes. Data are represented as mean ± SEM.

(B) Waterfall plot showing the relative tumor volume change from baseline in each individual mouse at day of best overall response in combination group (d42).

(C) Graph displaying the relative body weight change. Data are represented as mean ± SEM.